Company history

Nipro did not begin in glass distribution but in reconditioning light bulbs. In 1947 Sano Minoru, then twenty-one, set up a bulb-reworking business in Otsu, Shiga, and by 1950 was running the Biwako Bulb Works — the years in which his dealings with Nippon Electric Glass began. Glass-forming technique had reached Japan largely through the manufacture of bulbs and vacuum tubes, and Sano took it out of that process and mechanised work that the trade still did by hand. “It was through making light bulbs,” he said later, “that we acquired the technology of processing glass.”

In July 1954, on becoming Nippon Electric Glass’s sole agent for western Japan, he founded Nihon Glass Shoji in Kyoto and began selling glass tubing for ampoules and tablet bottles — the year the annual reports treat as the company’s founding. The mechanising instinct transferred immediately: Nipro automated ampoule-tube forming that same year, and as the machines spread, the roughly 300 ampoule processors then working in Osaka were reduced to about fifteen. A company that had set out to sell tubing had redrawn the structure of the industry it sold into.

What emerged was neither a trading house nor a manufacturer. “We are essentially a trading company,” Sano put it, “but what we do is industrial and technical” — the principle being to sell technique before goods. Nipro built the production machinery its customers needed and then supplied the material those machines consumed, so the relationship survived any change of product. When it developed an automatic former for vacuum-flask liners in 1963, overseas buyers queued up and Sano refused to export it: flasks were an Osaka local industry, and selling the machine abroad would have damaged his own customers’ base. The same logic carried the company into medicine. Ampoule tubing had made pharmaceutical firms its customers, so in April 1965 it began selling them infusion sets — devices, deliberately not drugs, which would have put it in competition with the very firms it supplied. It bought the needle maker Tomizawa Seisakusho in 1969 and, in 1972, a company called Japan Plastic Specialities, renaming it Nipro — the name that would eventually become the parent’s own.

Renamed Nissho in May 1977, the company opened a technical development centre in Kusatsu and pushed into disposable devices — syringes and coil dialysers from 1974, a dedicated plant at Odate in 1981. The rationale was specific: needles had been boiled and reused, and boiling does not kill hepatitis B, so safety required disposability — but a product that substitutes for nursing labour only spreads if it is cheap. A firm that could build its own mass-production machinery was unusually well placed to supply both conditions.

Through the 1980s Nissho carried three businesses of entirely different character — glass materials, supermarkets and medical devices — and Sano defended the mix as doctrine rather than drift: enter new fields while the existing ones are still strong, and keep low-technology businesses at the core alongside the high-technology ones. The payoff was not the one hindsight expects. When Nissho listed on the Osaka exchange in February 1987, medical devices were loss-making and analysts were telling it to quit medicine; it was the retail arm that supplied the sales scale needed to qualify. In the year to March 1986 ordinary profit split almost evenly three ways — 35.0% medical, 33.6% materials, 31.4% stores. Sales in the year to March 1987 were $446.1M (¥65bn), needle output had reached over 200 million a month, and the Nipro brand was better known abroad than at home.

Overseas production followed the economics of low-priced, bulky goods: Thailand in 1988, Belgium in 1991, Shanghai in 1994, Brazil in 1995, the United States in 1996. A stake in Hishiyama Seiyaku in 1988 added pharmaceuticals beside devices. But the upstream grip that had built the company also produced its first public reckoning. Holding exclusive western-Japan rights to Nippon Electric Glass tubing, Nipro demanded that the ampoule maker Naigai stop importing from Korea, then raised that customer’s price by 20% and finally cut off supply. The Osaka District Court found for Naigai in March 1999, the Japan Fair Trade Commission raided in June, and in February 2000 issued a cease-and-desist recommendation. The company that had refused to export a machine in order to protect its customers’ industry had closed off an ampoule maker’s choice of suppliers.

In April 2001 the company absorbed its own sales subsidiary and took its name, becoming Nipro Corporation; two months later it split the supermarket division into a new company called Nissho. The glass merchant’s name went with the shops. By 2002 Nipro was being written up as the counter-example to focus: medical devices produced 45% of sales and nearly 80% of operating profit, its dialysers held roughly 30% of the world market, and yet it kept a retail arm earning a 1.6% margin. Sano’s answer to the analysts was that a manager who thinks only about present profit cannot adapt, and that balancing long against short is the job itself.

Four years later he sold it anyway. Nissho went to Hankyu Department Stores in July 2006 and the drugstore chain to Kirindo in December, ending forty-three years in retail; the stated reason was not profitability but concentrating resources on devices and drugs. Revenue fell 10.9% to ¥184.3bn in the year to March 2007 while operating profit rose 5.9% — sales given up for margin. The sequence Sano had described was simply complete: materials and shops had earned while medicine and pharmaceuticals grew up, and the loss-making drug business had turned profitable in 1999.

The proceeds went, of all places, back into glass. Nipro built or bought container-glass operations in India and China from 2010, took Amcor’s medical glass business with its French and US plants in 2011, added Russian and German capacity through 2012, and turned a domestic sideline into a global division. Capital ties followed the trade: Nippon Electric Glass, the supplier Sano had first dealt with in 1950, bought its way to 10.4% of Nipro by August 2011 for about $130.4M (¥10bn) and later to 14.0% — while Nipro was itself Nippon Electric Glass’s largest shareholder. Sano Minoru died in May 2012, sixty-five years after the light bulbs and fifty-eight at the head of the company.

Sano Yoshihiko, the founder’s nephew, took over in the year to March 2012 with a structural problem: revenue concentrated in low-priced consumables. His answer was acquisition. Goodman brought catheters in 2013, InfraReDx imaging, NexMed orthopaedics in 2017, Machida Seisakusho endoscopes in 2018 — products chosen on grounds other than price, sold through the distribution built by needles and infusion sets. Generic drugs were scaled the same way, with Tanabe’s sales arm becoming Nipro ES Pharma in 2017 and two plants added in 2019. Group headcount went from 23,153 in the year to March 2015 to 38,593 in the year to March 2026, and sales doubled from ¥325.1bn to $4.2B (¥661bn).

The margin did not follow. Operating profit in the year to March 2026 was $237.7M (¥38bn) — a 5.7% operating margin, and as low as 3.3% in the year to March 2023. Against the ¥64.5bn of 1987, sales are ten times larger and the margin has not moved. The founding business is the worst of it: pharma packaging turned over ¥54.7bn in the year to March 2026 and lost ¥1.6bn, as glass had lost money intermittently for a decade after the Amcor deal made it global. Capital spending in the division still runs ahead of depreciation; no decision to fold it has been taken.

On 26 June 2025 Yamazaki Tsuyoshi, who joined in 1991 and ran the international business, became president — the first from outside the founding family since 1954, and the first change at the top in thirteen years. The mid-term plan he had presented that May targets ¥781.0bn of sales and a 7.0% operating margin by fiscal 2027 under the headings “lean management” and “thorough elimination of waste,” and states plainly that the product strategy includes withdrawal from unprofitable and non-synergistic products. That is the exact inverse of the 2002 position that refusing to shed loss-making divisions was a proof of governance — though Sano’s argument held on its own terms, since retail was in fact released once the businesses it was funding had grown. What separates diversification that keeps everything from management that discards is whether there is still a next business being raised. The share register has moved too: Nippon Electric Glass has fallen from 14.0% to 5.19% and third place, and trust banks and foreign institutions now sit above it.